Intervención desde el modelo cognitivo comportamental para el tratamiento de esquizofrenia paranoide y trastornos mentales del comportamiento por el uso de múltiples drogas y uso de otras sustancias psicoactivas: caso de estudio
| datacite.rights | http://purl.org/coar/access_right/c_16ec | |
| dc.contributor.advisor | Sánchez-Villegas, Milgen | |
| dc.contributor.author | Arrazola Mercado, Jennifer | |
| dc.contributor.author | Mercado Miranda, Estefany Johana | |
| dc.contributor.author | Mangones Austin, Vanessa Del Carmen | |
| dc.date.accessioned | 2023-08-02T14:53:59Z | |
| dc.date.available | 2023-08-02T14:53:59Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | El presente estudio de caso se centra en un paciente llamado MR, quien presenta esquizofrenia paranoide y trastornos mentales relacionados con el consumo de múltiples drogas y sustancias psicoactivas. Se implementó un plan de intervención basado en la terapia cognitivo-conductual para abordar los aspectos cognitivos negativos y los comportamientos problemáticos del paciente. El primer objetivo del plan de intervención fue reducir el consumo de cannabis por parte de MR. Para lograr esto, se brindó al paciente una explicación detallada sobre las consecuencias y riesgos del consumo de esta sustancia, así como opciones para prevenir recaída. Además, se implementó la técnica de relajación muscular progresiva y se asignaron tareas para el hogar, que incluían el repaso de las sesiones, la anticipación de problemas y la preparación para posibles resultados negativos. En cuanto al problema de la sensopercepción, el objetivo fue mejorar el grado de funcionalidad del paciente. Se proporcionó orientación sobre el diagnóstico de esquizofrenia paranoide, brindando información clara sobre los síntomas, el manejo, las causas y la importancia del tratamiento. Además, se utilizó la técnica de control y programación de actividades para fomentar la participación de MR en la mayor cantidad posible de actividades deseadas. Estas intervenciones se desarrollaron en un conjunto específico de sesiones. Como resultado, se observaron avances terapéuticos significativos. MR adquirió una mayor conciencia de las consecuencias negativas del consumo de sustancias psicoactivas y de su propio diagnóstico. | spa |
| dc.description.abstract | This case study focuses on a patient named MR, who presents with paranoid schizophrenia and mental disorders related to the use of multiple drugs and psychoactive substances. An intervention plan based on cognitive-behavioral therapy was implemented to address the patient's negative cognitive aspects and problem behaviors. The first objective of the intervention plan was to reduce the use of cannabis by MR. To achieve this, the patient was provided with a detailed explanation of the consequences and risks of consuming this substance, as well as options to prevent relapse. In addition, the progressive muscle relaxation technique was implemented and homework was assigned, which included reviewing the sessions, anticipating problems, and preparing for possible negative outcomes. Regarding the problem of sensory perception, the objective was to improve the degree of functionality of the patient. Guidance on the diagnosis of paranoid schizophrenia was provided, giving clear information on symptoms, management, causes and the importance of treatment. In addition, the activity control and scheduling technique was perfected to encourage MR participation in as many desired activities as possible. These interventions were developed in a specific set of sessions. As a result, significant therapeutic advances were observed. MR became more aware of the negative consequences of psychoactive substance use and of his own diagnosis. | eng |
| dc.format.mimetype | ||
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/13058 | |
| dc.language.iso | spa | |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias Jurídicas y Sociales | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Esquizofrenia paranoide | spa |
| dc.subject | Trastornos mentales | spa |
| dc.subject | Sustancias psicoactivas | spa |
| dc.subject | Modelo cognitivo conductual | spa |
| dc.subject | Paranoid schizophrenia | eng |
| dc.subject | Mental disorders | eng |
| dc.subject | Psychoactive substances | eng |
| dc.subject | Cognitive behavioral model | eng |
| dc.title | Intervención desde el modelo cognitivo comportamental para el tratamiento de esquizofrenia paranoide y trastornos mentales del comportamiento por el uso de múltiples drogas y uso de otras sustancias psicoactivas: caso de estudio | spa |
| dc.type.driver | info:eu-repo/semantics/other | |
| dc.type.spa | Otros | |
| dcterms.references | Aich, T., Mahato, A., y Subedi, S. (2017). Cognitive Impairment in Schizophrenia: Current Perspective. Journal of Psychiatrists’ Association of Nepal, 5(1), 5–13. https://doi.org/10.3126/jpan.v5i1.18324 | eng |
| dcterms.references | American Psychiatric Association. (2013). Cautionary Statement for Forensic Use of DSM-5. In Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 20, 87-88., 100-104.,155- 165.,). American Psychiatric Association. | eng |
| dcterms.references | American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders. (5th ed.). DSM-5. American Psychiatric Publishing. | eng |
| dcterms.references | Barrowclough, C., Haddock, G., Lobban, F., y Jones, S. (2015). Group Cognitive-Behavioural Therapy for Schizophrenia: Randomised Controlled Trial. The British Journal of Psychiatry, 206 (6), 494-502. | eng |
| dcterms.references | Beck, A. y Rector, N. (2014). Cognitive approaches to schizophrenia: Theory and therapy. Annual Review of Clinical Psychology, 10, 167-195. | eng |
| dcterms.references | Beck, A., Rector, N. y Stolar, N. (2009). Cognitive therapy of schizophrenia: A new therapy for the new millennium. American Journal of Psychotherapy, 63(2), 131-151. | eng |
| dcterms.references | Beck, A., Rector, N., Stolar, N., y Grant, P. (2009). Schizophrenia: Cognitive Theory, Research, and Therapy. Guilford Press. | eng |
| dcterms.references | Carbonell-Campos, J., Braquehais, M., García-Parés, G., y Gómez-Durán, E. (2019). Guía clínica de atención en esquizofrenia y trastornos psicóticos. Revista de Psiquiatría y Salud Mental, 12(3), 158-183. | spa |
| dcterms.references | Carbonell-Campos, J., Elices, M., Grau-López, L., Soler, J., y Pérez, V. (2019). Drug abuse and psychotic symptoms: A critical review of pharmacological and psychostimulant-induced psychosis. Journal of Psychopharmacology, 33(3), 355-371. | eng |
| dcterms.references | Carbonell-Campos, J., Prat, G., Escudero, J. y Sánchez-Mora, C. (2019). Comorbidity of substance use disorder and psychiatric disorders: A qualitative study. Frontiers in Psychology, 10, 57. https://doi.org/10.3389/fpsyg.2019.00057 | eng |
| dcterms.references | Cerdá, M., Santaella-Tenorio, J., Marshall, B., Kim, J., Martins, S. y Wall, M. (2016). Association between prescription drug misuse and psychiatric disorders in the USA. Addiction, 111(6), 1- 9. | eng |
| dcterms.references | Drake, R., O'Neal, E. y Wallach, M. (2008). A Systematic Review of Psychosocial Research on Psychosocial Interventions for People with Co-occurring Severe Mental and Substance Use Disorders. Journal of Substance Abuse Treatment, 34(1), 123-138. | eng |
| dcterms.references | Drake, R., Wallach, M., Alverson, H., y Mueser, K. (2016). Dual diagnosis: 15 years of progress. Psychiatric Services, 67(7), 743-749. https://doi.org/10.1176/appi.ps.201500263 | eng |
| dcterms.references | Encuesta Nacional de Salud Mental (2015). Bogotá D.C.: Ministerio de Salud y Protección Social - COLCIENCIAS; 2018. Recuperado de http://www.odc.gov.co/Portals/1/publicaciones/pdf/consumo/estudios/nacionales/O03110201 5sal ud_mental_tomoI.pdf | spa |
| dcterms.references | García, M., López, M., y Torres, P. (2018). Programa de intervención cognitivo-conductual en personas con esquizofrenia y trastornos por uso de sustancias psicoactivas. Revista Argentina de Clínica Psicológica, 27(3), 241-252. | spa |
| dcterms.references | Gaudiano, B., Weinstock, L. y Miller, I. (2009). Improving treatment engagement and outcomes for depression by integrating cognitive-behavioral therapy and pharmacotherapy: A randomized controlled trial. Psychotherapy and Psychosomatics, 78(6), 385-397. https://doi.org/10.1159/000235982 | eng |
| dcterms.references | Gómez-Benito, J., Guilera, G., Barrios, M., Rojo, E., y Sánchez-Morla, E. (2017). Adherence to treatment in schizophrenia: A multi-methods approach. European Journal of Psychiatry, 31(1), 9-19. | eng |
| dcterms.references | Gómez-Benito, J., Ruiz de Apodaca, R., Moreno-Küstner, B. y Hernandez-Mezquita, M. (2017). Substance use disorders in outpatients with schizophrenia: prevalence and sociodemographic and clinical correlates. Comprehensive psychiatry, 73, 145-151. | eng |
| dcterms.references | Gómez-Benito, J., Ruiz-Muñoz, D., y Guilera, G. (2017). Substance use and schizophrenia: Effects on symptomatology, functioning and cognition. Schizophrenia Research and Treatment. https://doi.org/10.1155/2017/7859387 | eng |
| dcterms.references | Granholm, E., Holden, J., Link, P., McQuaid, J. y Jeste, D. (2013). Randomized controlled trial of cognitive behavioral social skills training for older consumers with schizophrenia: Defeatist performance attitudes and functional outcome. The American Journal of Geriatric Psychiatry, 21(3), 251-262. | eng |
| dcterms.references | Grant, B., Goldstein, R., Chou, S., Huang, B., Stinson, F., Dawson, D. y Hasin, D. (2016). Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Molecular Psychiatry, 21(6), 1-13. | eng |
| dcterms.references | Grant, P. Hoyt, W. y Beck, A. (2018). Assessment and treatment of negative symptoms in schizophrenia: An update. Psychiatry Journal. https://doi.org/10.1155/2018/8931849 | eng |
| dcterms.references | Jauhar, S., McKenna, P. Radua, J., Fung, E., Salvador, R. y Laws, K. (2014). Cognitive-behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. The British Journal of Psychiatry, 204(1), 20-29. https://doi.org/10.1192/bjp.bp.112.116285 | eng |
| dcterms.references | Kessler, R., Chiu, W., Demler, O. y Walters, E. (2005). Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617-627. | eng |
| dcterms.references | Lai, H., Cleary, M., Sitharthan, T. y Hunt, G. (2017). Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta- analysis. Drug and Alcohol Dependence, 174, 1-13. | eng |
| dcterms.references | Rounsaville, B., Weissman, M., Prusoff, B. y Herbst, J. (2008). Psychopathology in Substance Abusers: Diagnosis and Treatment. The American Journal of Drug and Alcohol Abuse, 8(2), 137-150. | eng |
| dcterms.references | Santaella-Tenorio, J., Cerdá, M., Marshall, B., Wall, M., Kim, J., Martins, S. y Keyes, K. (2016). US National Study of Substance Use Patterns Among Adults With SUD Histories: The Role of States in Reducing Behavioral Health Disparities. Medical Care, 54(9), 891-898. | eng |
| dcterms.references | Volkow, N., Koob, G. y McLellan, A. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine, 374(4), 363-371. | eng |
| dcterms.references | Wallach, M. y Drake, R. (2015). Substance abuse and rehabilitation for persons with co-occurring psychiatric and substance use disorders. Social Work in Public Health, 30(2), 115-129. | eng |
| dcterms.references | Wallach, M., O'Neal, E. y Drake, R. (2014). The Roots of Dual Diagnosis: A Retrospective Analysis of Psychiatric Comorbidity in the Treatment of Substance Use Disorders. Substance Use & Misuse, 49(10), 1277-1284. | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | |
| sb.programa | Especialización en Psicología Clínica | spa |
| sb.sede | Sede Barranquilla | spa |